Integra Lifesciences Holdings Stock Alpha and Beta Analysis
| IART Stock | USD 22.49 0.22 0.97% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Integra LifeSciences Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Integra LifeSciences over a specified time horizon. Remember, high Integra LifeSciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Integra LifeSciences' market risk premium analysis include:
Beta 1.3 | Alpha 0.023 | Risk 3.13 | Sharpe Ratio 0.0267 | Expected Return 0.0836 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Integra |
Integra LifeSciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Integra LifeSciences market risk premium is the additional return an investor will receive from holding Integra LifeSciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Integra LifeSciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Integra LifeSciences' performance over market.| α | 0.02 | β | 1.30 |
Integra LifeSciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Integra LifeSciences' Buy-and-hold return. Our buy-and-hold chart shows how Integra LifeSciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Integra LifeSciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Integra LifeSciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Integra LifeSciences shares will generate the highest return on investment. By understating and applying Integra LifeSciences stock market price indicators, traders can identify Integra LifeSciences position entry and exit signals to maximize returns.
Integra LifeSciences Return and Market Media
The median price of Integra LifeSciences for the period between Sun, Dec 22, 2024 and Sat, Mar 22, 2025 is 23.02 with a coefficient of variation of 6.57. The daily time series for the period is distributed with a sample standard deviation of 1.54, arithmetic mean of 23.47, and mean deviation of 1.32. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | INTEGRA ANNOUNCES RECORD 2024 GOLD PRODUCTION OF 72,229 OUNCES FROM FLORIDA CANYON, STRONG YEAR-END CASH POSITION OF 52 MILLION, AND IMPLEMENTATION OF PRICE PRO... | 01/22/2025 |
2 | Notice To Long-Term Integra Lifesciences Holdings Corporation Shareholders Grabar Law Investigates Claims on Your Behalf | 02/04/2025 |
3 | Integra Lifesciences Holdings Corp Reports Fourth Quarter and Full-Year 2024 Financial ... | 02/25/2025 |
4 | INTEGRA ALERT Bragar Eagel Squire, P.C. ... | 02/26/2025 |
5 | Integra Gold Stock Passes Below 200 Day Moving Average Time to Sell | 02/28/2025 |
6 | Integra Q4 Earnings Beat Estimates, Revenues Rise YY, Stock Up | 03/03/2025 |
7 | Disposition of 324 shares by Singh Harvinder of Integra LifeSciences at 22.61 subject to Rule 16b-3 | 03/10/2025 |
8 | Disposition of 647 shares by Singh Harvinder of Integra LifeSciences at 23.95 subject to Rule 16b-3 | 03/11/2025 |
9 | ClickHouse adquiere HyperDX para acelerar el futuro de la observabilidad | 03/13/2025 |
10 | 3 Reasons IART is Risky and 1 Stock to Buy Instead | 03/14/2025 |
11 | Res Integra en Ohmium zullen een project voor groene waterstof van vier megawatt in Sicili ontwikkelen | 03/18/2025 |
12 | Acquisition by Singh Harvinder of 7140 shares of Integra LifeSciences subject to Rule 16b-3 | 03/21/2025 |
About Integra LifeSciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Integra or other stocks. Alpha measures the amount that position in Integra LifeSciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | |
| Dividend Yield | 3.22E-4 | 3.06E-4 |
| Price To Sales Ratio | 1.08 | 1.03 |
Integra LifeSciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Integra LifeSciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Integra LifeSciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Integra LifeSciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Integra LifeSciences. Please utilize our Beneish M Score to check the likelihood of Integra LifeSciences' management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Integra LifeSciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.